Long-term effects of pioglitazone versus gliclazide on hepatic and humoral coagulation factors in patients with type 2 diabetes

Diabetes and Vascular Disease Research

Volumn 4, Issue 3, 2007, Pages 226-230

  Perriello, Gabriele ^a   Pampanelli, Simone ^a   Brunetti, Paolo ^a   Di Pietro, Cinzia ^b   Mariz, Segundo ^c  

^a UNIVERSITY OF PERUGIA   (Italy)

^b Takeda Italy   (Italy)

^c TGRD (Europe)   (United Kingdom)

Author keywords

Cardiovascular disease; Coagulation; Diabetes; Gliclazide; Pioglitazone; Thrombosis

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR; GLICLAZIDE; PIOGLITAZONE; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; BLOOD COAGULATION FACTORS; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GLICLAZIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LIVER; MALE; MIDDLE AGED; THIAZOLIDINEDIONES; TIME FACTORS; TREATMENT OUTCOME;

EID: 34948885549     PISSN: 14791641     EISSN: None     Source Type: Journal    
DOI: 10.3132/dvdr.2007.044     Document Type: Article

References (32)

1. Schnell O, Standl E. Impaired glucose tolerance, diabetes, and cardiovascular disease. Endocr Pract 2006;12(suppl 1):16-19.
2. Thorand B, Baumert J, Chambless L et al. Elevated markers of endothelial dysfunction predict type 2 diabetes mellitus in middle-aged men and women from the general population. Arterioscler Thromb Vasc Biol 2006;26:398-405.
3. Colwell JA, Nesto RW. The platelet in diabetes. Focus on prevention of ischemic events. Diabetes Care 2003;26:2181-8.
4. Candido R, Zanetti M. Current perspective. Diabetic vascular disease: from endothelial dysfunction to atherosclerosis. Ital Heart J 2005;6:703-20.
5. Schneider DJ. Abnormalities of coagulation, platelet function, and fibrinolysis associated with syndromes of insulin resistance. Coron Artery Dis 2005;16:473-6.
6. Jokl R, Colwell JA. Arterial thrombosis and atherosclerosis in diabetes. Diabetes Metab Rev 1997;5:1-15.
7. Jokl R, Colwell JA. Clotting disorders in diabetes. In: Alberti KGMM, Zimmet P, Defronzo R, Koen H, ed. International Textbook of Diabetes Mellitus. 2nd edition. Chichester: Wiley, 1997:1543-57.
8. Blann AD. Plasma von Willebrand factor, thrombosis, and the endothelium: the first 30 years. Thromb Haemost 2006;95:49-55.
9. Juhan-Vague I, Alessi MC, Mavri A et al. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance, and vascular risk. J Thromb Haemost 2003;1:1575-9.
10. Vaughan DE. PAI-1 and atherothrombosis. J Thromb Haemost 2005;3:1879-83.
11. Vaidyula VR, Rao AK, Mozzoli M et al. Effects of hyperglycaemia and hyperinsulinemia on circulating tissue factor procoagulant activity and platelet CD40 ligand. Diabetes 2006;55:202-08.
12. Stegenga ME, van der Crabben SN, Levi M et al. Hyperglycemia stimulated coagulation, whereas hyperinsulinemia impairs fibrinolysis in healthy humans. Diabetes 2006;55:1807-12.
13. Verges B. Clinical interest of PPARs ligands. Particular benefit in type 2 diabetes and metabolic syndrome. Diabetes Metab 2004;30:7-12.
14. Grant PJ. Beneficial effects of metformin on haemostasis and vascular function in man. Diabetes Metab 2003;29:S44-52.
15. Chu JW, Abbasi F, Lamendola C et al. Effect of rosiglitazone on circulating vascular and inflammatory markers in insulin-resistant subjects. Diabetes Vase Dis Res 2005;2:37-41.
16. Kruszynska YT, Yu JG, Olefsky JM et al. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes 2000;49:633-9.
17. Derosa G, Cicero AF, Gaddi A et al. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Diabetes Res Clin Pract 2005;69:5-13.
18. De Jager J, Kooy A, Lehert P et al. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med 2005;257:100-09.
19. Fonseca V, Theuma P, Mudaliar S et al. Diabetes treatments have differential effects on non-traditional cardiovascular risk factors. J Diabetes Complications 2006;20:14-20.
20. Perriello G, Pampanelli S, Di Pietro C et al. Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with type 2 diabetes. Diabet Med 2006;23:246-52.
21. Chandler WL, Alessi MC, Aillaud MF et al. Formation, inhibition and clearance of plasmin in vivo. Haemostasis 2000;30:204-18.
22. Spiess B, Chandler WL. Genetic basis of procoagulant and fibrinolytic perioperative adverse events. Best Practice & Research Clinical Anaesthesiology 2001;15:195-211.
23. Vischer UM. von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Haemost 2006;4:1186-93.
24. Cefalu WT, Schneider DJ, Carlson HE et al. Effect of combination glipazide GITS/metformin on fibrinolytic and metabolic parameters in poorly controlled type 2 diabetic subjects. Diabetes Care 2002;25:2123-8.
25. Gin H, Roudaut MF, Vergnot V et al. Effect of metformin on fibrinolytic parameters in insulin-treated, type 2 diabetic patients. Diabetes Metab 2003;29:505-08.
26. Grant PJ, Stickland MH, Booth NA et al. Metformin causes a reduction in basal and post-venous occlusion plasminogen activator inhibitor-1 in type 2 diabetic patients. Diabet Med 1991;8:361-5.
27. Charles MA, Morange P, Eschwege E et al. Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese non-diabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity. Diabetes Care 1998;21:1967-72.
28. Caballero AE, Delgado A, Aguilar-Salinas CA et al. The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled randomized clinical trial. J Clin Endocrinol Metab 2004;89:3943-8.
29. Liu HB, Hu YS, Medcalf RL et al. Thiazolidinediones inhibit TNFalpha induction of PAI-1 independent of PPARgamma activation. Biochem Biophys Res Commun 2005;334:30-7.
30. Pfutzner A, Marx N, Lubben G et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 2005;45:1925-31.
31. Yamaguchi M, Nishimura F, Naruishi H et al. Thiazolidinedione (pioglitazone) blocks P. gingivalis and F. nucleatum, but not E. coli, lipopolysaccharide (LPS)-induced interleukin-6 (IL-6) production in adipocytes. J Dent Res 2005;84:240-4.
32. Blann AD, Lip GY. Effects of C-reactive protein on the release of von Willebrand factor, E-selectin, thrombomodulin and intercellular adhesion molecule-1 from human umbilical vein endothelial cells. Blood Coagul Fibrinolysis 2003;14:335-40.